Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:17:07 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:CSLLY - CSL LTD SPON ADR EACH REPR 0.5 ORD - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CSLLY - Qnot subscribed64.22+1.211.9210.013,31065461.11  65.82  61.1189.71  54.1015:58:38Dec 0715 min RT 2¢

Recent Trades - Last 10 of 654
Time ETExPriceChangeVolume
15:58:38Q64.221.21100
15:58:38Q64.221.2176
15:58:23Q64.241.23100
15:53:52Q64.221.21100
15:53:23Q64.1951.18518
15:51:25Q64.241.23100
15:51:22Q64.1951.185276
15:50:50Q64.1951.18530
15:50:46Q64.2391.22925
15:50:41Q64.1951.1853

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-07 12:01U:CSLLYNews ReleaseData Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX(TM) (etranacogene dezaparvovec-drlb) Over Five Years
2025-10-26 22:30U:CSLLYNews ReleaseCSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
2025-10-21 08:30U:CSLLYNews ReleaseRecent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
2025-10-06 08:00U:CSLLYNews ReleaseCSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX(TM) (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
2025-09-26 02:30U:CSLLYNews ReleaseCSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
2025-08-08 08:00U:CSLLYNews ReleaseHealth Canada Has Authorized CSL's ANDEMBRY(TM) (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
2025-06-16 19:48U:CSLLYNews ReleaseU.S. Food and Drug Administration Approves CSL's ANDEMBRY(TM) (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
2025-05-23 04:00U:CSLLYNews ReleaseEngland's NICE recommends FILSPARI(TM) (sparsentan) as a treatment option for IgA nephropathy
2025-04-29 02:00U:CSLLYNews ReleaseCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI(TM) in IgA Nephropathy
2025-02-20 09:13U:CSLLYNews ReleaseCSL Receives Approval in Japan for ANDEMBRY(TM) (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
2025-02-14 08:30U:CSLLYNews ReleaseEuropean Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE(TM), the First Self-amplifying mRNA COVID-19 Vaccine
2025-02-13 07:00U:CSLLYNews ReleaseEuropean Commission Approves CSL's ANDEMBRY(TM) (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
2025-02-07 09:12U:CSLLYNews ReleaseCSL Behring's Gene Therapy HEMGENIX(TM) (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B